Wedbush Securities Inc Invitae Corp Transaction History

Wedbush Securities Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.05 - $1.63 $1,150 - $1,786	-1,096 Reduced 9.13%	10,905 $12,000
Q4 2022 Jan 31, 2023	SELL	$1.71 - $3.61 $3,336 - $7,043	-1,951 Reduced 13.98%	12,001 $22,000
Q3 2022 Oct 18, 2022	SELL	$1.9 - $8.63 $5,859 - $26,614	-3,084 Reduced 18.1%	13,952 $34,000
Q2 2022 Jul 21, 2022	SELL	$2.13 - $9.01 $31,555 - $133,483	-14,815 Reduced 46.51%	17,036 $41,000
Q1 2022 Apr 19, 2022	SELL	$6.28 - $15.59 $31,393 - $77,934	-4,999 Reduced 13.57%	31,851 $253,000
Q4 2021 Jan 13, 2022	SELL	$14.7 - $28.67 $26,562 - $51,806	-1,807 Reduced 4.67%	36,850 $562,000
Q3 2021 Oct 08, 2021	BUY	$24.31 - $33.6 $93,860 - $129,729	3,861 Added 11.1%	38,657 $1.1 Million
Q2 2021 Jul 27, 2021	SELL	$26.09 - $40.4 $29,716 - $46,015	-1,139 Reduced 3.17%	34,796 $1.17 Million
Q1 2021 Apr 26, 2021	BUY	$33.06 - $56.93 $869,577 - $1.5 Million	26,303 Added 273.08%	35,935 $1.37 Million
Q4 2020 Feb 16, 2021	BUY	$39.09 - $57.4 $182,980 - $268,689	4,681 Added 94.55%	9,632 $403,000
Q3 2020 Oct 20, 2020	BUY	$28.43 - $44.67 $140,756 - $221,161	4,951 New	4,951 $215,000

1.92M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.